1/91
Looks like no tags are added yet.
Name | Mastery | Learn | Test | Matching | Spaced | Call with Kai | Chat |
|---|
No analytics yet
Send a link to your students to track their progress
52.Which of the following statements is TRUE regarding plasma elevations of rosuvastatin in Asians? A. It is higher than in Caucasians B. It entails higher dose requirements C. It is similar to the elevations in Caucasians D. It is lower than in Caucasians
A. It is higher than in Caucasians
34.What is the most common side effect of using insulin to treat diabetes mellitus type 2? A. Headaches B. Insulin resistance C. Muscle wasting D. Gastrointestinal adverse effects E. Hypoglycemia
E. Hypoglycemia
53.Which of the following drugs can potentially mask the symptoms of hypoglycemia in a diabetic patient? A. Antipsychotic agents B. Haloperidol C. Quinolones D. Beta blockers
D. Beta blockers
3.If a diabetic patient who has been taking insulin has been hospitalized for a different illness, which of the following management principles is CORRECT? A. Insulin should be stopped if the blood glucose is below 13 mmol/L B. Insulin should be doubled if plasma glucose rises and stays above 13 mmol/L C. Insulin should be decreased appropriately if plasma glucose falls below 13 mmol/L D. Insulin should not be stopped, even if the patient cannot eat
D. Insulin should not be stopped, even if the patient cannot eat
5.In which of the following conditions should insulin be started in a patient with DM Type 2? A. Patient's 2-hour postprandial RBS remain elevated despite combination metformin and GLP-1 agonist B. Patient's HbA1c level is not yet controlled despite 3 oral hypoglycemic agents being taken daily for 3 months C. Patient's FBS is not yet controlled despite 2 oral hypoglycemic agents being taken daily for 2+ months D. Patient's preprandial glucose remains uncontrolled despite maximum dose of metformin given for 6 months
B. Patient's HbA1c level is not yet controlled despite 3 oral hypoglycemic agents being taken daily for 3 months
6.Which of the following non-pharmacologic treatment principles is recommended for diabetic patients? A. Daily vitamin supplementation and chromium supplementation to lower blood glucose B. Meals should have more grains, bread, and vegetables compared to lean meat, low-fat dairy, and butter C. Regular intake of red wine equal to one standard serving (100 mL) for antioxidant benefits D. Removing all sucrose and sucrose-containing food from the diet
B. Meals should have more grains, bread, and vegetables compared to lean meat, low-fat dairy, and butter
19.Which of the following patient characteristics makes it more reasonable to go for a LOWER TARGET level for glucose control compared to most other DM patients? A. Patient with no family history of DM Type 2 B. Patient with only 1 risk factor for CVD C. Patient with 1 year history of DM Type 2 D. Patient with no active CVD
D. Patient with no active CVD
29.If a diabetic patient who has been taking insulin has been hospitalized for a different illness, which of the following management principles is CORRECT? A. Insulin should be stopped if the blood glucose is below 13 mmol/L B. Insulin should doubled if plasma glucose rises and stays above 13 mmol/L C. Insulin should not be stopped, even if the patient cannot eat D. Insulin should be decreased appropriately if plasma glucose falls below 13 mmol/L
C. Insulin should not be stopped, even if the patient cannot eat
30.What is the target organ/tissue of SGLT-2 inhibitors? A. Hepatic tissue B. Pancreas C. Renal tubules D. Intestinal gut wall
C. Renal tubules
31.Headaches and nasopharyngitis are common side effects of which class of OHAs? A. SGLT-2 inhibitors B. Biguanides C. Sulfonylureas D. DPP-4 inhibitors
D. DPP-4 inhibitors
34.What is the most common side effect of using insulin to treat diabetes mellitus type 2? A. Headaches B. Insulin resistance C. Muscle wasting D. Gastrointestinal adverse effects E. Hypoglycemia
E. Hypoglycemia
35.What is the mechanism of metformin as an OHA? A. Inhibits glucose absorption from kidneys B. Increases tissue insulin sensitivity C. Increases insulin secretion D. Inhibits hepatic gluconeogenesis
D. Inhibits hepatic gluconeogenesis
36.Acarbose targets which of the following organs/tissues? A. Renal tubules B. Hepatic tissue C. Intestinal wall tissue D. Pancreatic tissue
C. Intestinal wall tissue
41.What is the usual starting dose for long-acting insulin? A. 0.05 u/kg BW B. 0.01 u/kg BW C. 0.1 u/kg BW D. 0.5 u/kg BW
C. 0.1 u/kg BW
43.Increased serum cholesterol levels can be seen as a side effect with which of the following medications? A. All of the drugs mentioned can cause weight gain B. Rosiglitazone C. Repaglinide D. Glipizide
B. Rosiglitazone
44.If you are a primary care physician assigned to remote locations, which of the following methods of glucose monitoring is acceptable as the minimum standard of care? A. Capillary blood meters B. Random blood sugar testing C. Colorimetric strips D. Fasting blood sugar testing
C. Colorimetric strips
45.What is the recommended starting dose and regimen for Metformin in DM Type 2 patients? A. 500 mg twice a day B. 1000 mg twice a day C. 1000 mg once a day D. 500 mg once a day
A. 500 mg twice a day
46.Purely non-pharmacologic treatment for newly-diagnosed diabetic patients can be trialed for how long before medication should be started? A. 1 month B. 3 months C. 4 months D. 2 months
B. 3 months
48.Which of the following hormones are released from the gut and stimulates insulin secretion by the pancreas? A. DPP-4 B. GLP-1 C. SGLT-2 D. Amylin
B. GLP-1
53.Which of the following drugs can potentially mask the symptoms of hypoglycemia in a diabetic patient? A. Antipsychotic agents B. Haloperidol C. Quinolones D. Beta blockers
D. Beta blockers
57.What is the most common cause of patients not following their initial metformin regimen? A. Inconvenient daily dosing schedule B. Intolerance to the gastric side effects C. Difficult obtaining the medication D. Drug interactions with their prescribed statin
B. Intolerance to the gastric side effects
59.What is the target organ/tissue of SGLT-2 inhibitors? A. Intestinal gut wall B. Renal tubules C. Pancreas D. Hepatic tissue
B. Renal tubules
2.Which of the following is the drug of choice for lowering LDL-cholesterol but may slightly increase risk for DM? A. Ezetimibe B. Evolocumab C. Statins D. Fenofibrate
C. Statins
4.Which anti-dyslipidemic agent may reduce absorption of fat-soluble vitamins? A. Colesevelam B. Evolocumab C. Rosuvastatin D. Ezetimibe
A. Colesevelam
8.Which anti-dyslipidemic agent has been shown to reduce LDL-cholesterol by up to 71%? A. PCSK9 inhibitors B. Cholesterol absorption inhibitors C. Bile acid sequestrants D. Moderate-intensity statins
A. PCSK9 inhibitors
9.This is an injectable anti-dyslipidemic agent given every 2 to 4 weeks: A. Atorvastatin B. Fenofibrate C. Evolocumab D. Ezetimibe
C. Evolocumab
11.Which of the following conditions may cause dyslipidemia? A. Hypothyroidism B. Intake of beta-2 agonists C. Increased physical activity D. Low-fat diet
A. Hypothyroidism
12.Treatment of statin intolerance includes which of the following principles? A. Increasing the statin dose B. Withholding vitamin D C. Increasing frequency of administration D. Use of non-statin therapies such as ezetimibe
D. Use of non-statin therapies such as ezetimibe
13.Mr. X was taking atorvastatin for dyslipidemia. He also started taking high doses of gemfibrozil upon his neighbor's advice. He started to have severe muscle aches prompting consult. He needs to be evaluated for this rare but life-threatening adverse drug reaction: A. Cerebral hemorrhage B. Gallstones C. Rhabdomyolysis D. Agranulocytosis
C. Rhabdomyolysis
16.What is the mechanism of action of evolocumab? A. Binds bile acids in the gut B. Inhibits PCSK9 C. Inhibits HMG-CoA reductase D. Decreases catabolism of ApoA1
B. Inhibits PCSK9
17.Which of the following is primarily used to treat hypertriglyceridemia? A. Fenofibrate B. Ezetimibe C. Probucol D. Simvastatin
A. Fenofibrate
18.This lipid-altering agent inhibits absorption of cholesterol: A. Probucol B. Atorvastatin C. Ezetimibe D. Gemfibrozil
C. Ezetimibe
21.Which of the following lipid profiles should be targeted for lowering in diabetic patients? A. HDL B. Triglycerides C. LDL D. IDL
C. LDL
24.What is a common adverse effect of HMG-CoA reductase inhibitors? A. Gallstones B. Hypertriglyceridemia C. Cancer D. Elevation in liver transaminases
D. Elevation in liver transaminases
26.If a diabetic patient needs to aggressively lower his lipid parameters, which statin is recommended? A. Lovastatin B. Simvastatin C. Pravastatin D. Atorvastatin
D. Atorvastatin
27.Which of the following is a risk factor for statin-associated muscle symptoms? A. Obesity B. Diabetes C. Male gender D. Age less than 50 years
B. Diabetes
28.Which of the following is primarily used to treat hypertriglyceridemia? A. Ezetimibe B. Probucol C. Simvastatin D. Fenofibrate
D. Fenofibrate
38.If a diabetic patient needs to aggressively lower his lipid parameters, which statin is recommended? A. Lovastatin B. Atorvastatin C. Simvastatin D. Pravastatin
B. Atorvastatin
39.Which of the following are considered high-intensity statins? A. Atorvastatin 40 mg B. Pravastatin 40 mg C. Simvastatin 40 mg D. Lovastatin 40 mg
A. Atorvastatin 40 mg
40.Which of the following is a risk factor for statin-associated muscle symptoms? A. Male gender B. Obesity C. Age less than 50 years D. Diabetes
D. Diabetes
42.This drug class in combination with statins has been shown to reduce CV events in a subgroup of patients with low HDL and high TG: A. Bile acid sequestrants B. Probucol C. Fibrates D. Niacin
C. Fibrates
55.Which anti-dyslipidemic agent must be used with caution in patients with cholelithiasis? A. PCSK9 inhibitors B. Fish oil C. Fibrates D. Statins
C. Fibrates
58.Which anti-dyslipidemic agent is well-known to induce skin flushing? A. Atorvastatin B. Niacin C. Alirocumab D. Gemfibrozil
B. Niacin
60.A 59-year-old male was given a lipid-altering agent. Both his LDL and HDL levels went down. Which of the following is the most likely agent? A. Rosuvastatin B. Probucol C. Fenofibrate D. Niacin
B. Probucol